Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined... see more

Recent & Breaking News (NDAQ:AGIO)

Agios Publishes 2024 Environmental, Social and Governance (ESG) Report

GlobeNewswire April 9, 2024

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

GlobeNewswire March 5, 2024

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

GlobeNewswire February 22, 2024

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

GlobeNewswire February 15, 2024

Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024

GlobeNewswire February 2, 2024

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

GlobeNewswire January 8, 2024

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

GlobeNewswire January 3, 2024

Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

GlobeNewswire January 2, 2024

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

GlobeNewswire December 9, 2023

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

GlobeNewswire November 20, 2023

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition

GlobeNewswire November 2, 2023

Agios Reports Business Highlights and Third Quarter 2023 Financial Results

GlobeNewswire November 2, 2023

Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023

GlobeNewswire October 19, 2023

Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023

GlobeNewswire August 29, 2023

Agios Reports Business Highlights and Second Quarter 2023 Financial Results

GlobeNewswire August 3, 2023

Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera

GlobeNewswire August 3, 2023

Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023

GlobeNewswire July 13, 2023

Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response

GlobeNewswire June 26, 2023

Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023

GlobeNewswire June 5, 2023

Agios Appoints Catherine Owen to Board of Directors

GlobeNewswire May 25, 2023